Adcomm Votes Unanimously for Lilly’s Alzheimer’s Treatment Donanemab
Despite concerns raised in FDA briefing documents about Eli Lilly’s Alzheimer’s treatment, donanemab, the committee concluded that the benefits outweighed the risks.
Adcomm Votes Unanimously for Lilly’s Alzheimer’s Treatment Donanemab Read More »
